LCLuigi Cantarutti

Luigi Cantarutti

*This is an algorithmically generated author record based on publicly available information.

Luigi Cantarutti has a total of 70 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Changing Empirical Antibiotic Prescribing Patterns Through a Clinical Decision Support System in Outpatient Paediatric Care in Italy: A Multicentre, Quality-Improvement Study

    by Giulia Brigadoi, Riccardo Boracchini, Cecilia Liberati, Lorenzo Chiusaroli, Marica De Pieri, Emelyne Gres, Lorenzo Tavernaro, Sofia Marchiorello, Luigi Cantarutti, Elisa Barbieri, et al.

    Background/Objectives: Respiratory tract infections (RTIs) represent one of the most frequent reasons for antibiotic prescribing in paediatric primary care. Clinical decision support systems (CDSS) offer a strategy to promote guideline-concordant prescribing, but evidence from real-world implementation remains limited. Methods: We conducted a cluster-level controlled before-and-after quality-improvement study among 15 family care paediatricians of an Italian paediatric primary care network. Antibiotic prescriptions for RTIs in children aged < 14 years were compared between November 2023–April 2024 and November 2024–April 2025 across three groups: CDSS only, CDSS plus multilingual caregiver leaflets, and no intervention. The CDSS, integrated into the software where health records were recorded, provided guideline-based treatment pathways and weight-based dosing. Episodes were identified via ICD-9-CM codes and validated free text in the Pedianet database; log-binomial regression estimated relative risk with 95% CI. Within-paediatrician correlation was accounted for in the analysis using a cluster-robust variance estimator. Results: A total of 7138 RTI episodes were included. The availability of a CDSS integrated into the electronic health record system was associated with an increased use of guideline-recommended first-line antibiotics for RTIs, although the increase in the use of amoxicillin reached statistical significance only for CAP in both intervention groups. Non-prescription rates remained unchanged across the intervention groups. The control group also showed temporal changes, including increased non-prescription for pharyngitis and reduced amoxicillin use for CAP. Conclusions: CDSS integration was associated with increased first-line antibiotic use for certain conditions. However, its limited effect on overall prescribing volume underscores the persistent role of diagnostic uncertainty. Future stewardship strategies may benefit from combining CDSSs with point-of-care testing and behavioural interventions.

  • Open Access

    Pediatricians’ Attitudes and Knowledge of RSV Immunization Products

    by Costanza Di Chiara, Pierre-Philippe Piché-Renaud, Vera Rigamonti, Anna Cantarutti, Cristina Calvo, Irene Rivero Calle, Antoni Soriano-Arandes, Carlo Giaquinto, Luigi Cantarutti, Daniele Donà, et al.

    Purpose Nirsevimab and the maternal vaccination in pregnancy are newly introduced prevention strategies against respiratory syncytial virus (RSV). This study evaluated pediatricians’ knowledge, attitudes, and barriers to RSV immunization in Italy and Cyprus/Greece, where nirsevimab had not yet been implemented, and in Spain, where it was introduced in 2023/2024. Methods A survey was distributed to pediatricians across Spain, Italy, and Cyprus/Greece in July-August/2024. Occupational characteristics, and knowledge, attitudes and practices toward palivizumab, nirsevimab, and the maternal vaccine were collected. Of 578 respondents (response rate=19.3%), 50% were from Spain, 40% from Italy, and 10% from Cyprus/Greece. As 90% of responses came from Spain and Italy, the main analysis focused on these two countries. Descriptive and univariate analyses (Chi-square or Fisher’s exact tests) were conducted. Results Respondents included pediatricians from community (51.7%), tertiary (30.4%), and primary/secondary care (17.9%) settings. Pediatricians were generally aware of RSV risk factors, without differences across countries. However, 245 (55.9%) and 375 (86.0%) participants reported average-to-low knowledge of nirsevimab and the maternal vaccine, respectively, with differences across countries (p=0.002). Despite limited knowledge, 311 (85.9%) pediatricians were willing to administer nirsevimab, and 319 (92.2%) supported its use for all infants. Nirsevimab administration’s barriers, including unfamiliarity and logistical challenges, were cited by 69 (20.0%) pediatricians. Regarding immunization preferences, 165 (47.4%) pediatricians were very likely to support the maternal vaccine over nirsevimab. Conclusions While pediatricians support RSV immunization, knowledge gaps and logistical barriers may hinder early-stage implementation. Optimizing education on RSV immunization will be crucial to improve uptake and prevention strategies. What’s Known on This Subject There is limited evidence regarding pediatricians’ attitudes and knowledge of nirsevimab and maternal RSV vaccination during pregnancy. What This Study Adds This multi-country survey evaluates pediatricians’ knowledge, attitudes, and barriers to RSV immunization in Italy and Cyprus/Greece, where nirsevimab had not yet been implemented, and in Spain, where it was introduced in 2023/2024.


  • Open Access

    Cost-Effectiveness of Influenza Vaccination in Healthy Children: A 10-Year Population-Based Study

    by Elisa Barbieri, Yuxi Wang, Anna Cantarutti, Antonio Scamarcia, Luigi Cantarutti, Giovanni Corrao, Aleksandra Torbica, Carlo Giaquinto

    Background/Objectives: Seasonal influenza annually puts a significant burden on the pediatric population, especially the youngest, causing severe illness and death. Additionally, associated healthcare costs cause a significant financial strain on healthcare systems. While vaccination is the most effective prevention method, its cost-effectiveness for healthy children remains unassessed. Methods: Using the Pedianet database spanning from 2009 to 2019, we analyzed influenza cases among 6-month-olds to 14-year-olds in Italy. Data included influenza-related medical visits, prescriptions, exams, emergency visits, hospitalizations, and costs. Adverse events and quality-adjusted life years (QALYs) were considered from the existing literature. A static decision-tree model compared annual vaccination strategies, assessing probabilities for influenza or influenza-like illnesses by vaccination status. Incremental cost-effectiveness ratios (ICERs) were calculated, along with sensitivity analyses and cost-effectiveness acceptability curve generation. Results: Mean total influenza costs for vaccinated children averaged EUR 18.6 (range 0–3175.9, including EUR 15.79 for the influenza vaccination), whereas costs for unvaccinated children were consistently lower at around EUR 4.6 (range 0–3250.1). The average ICER for years where vaccine and virus strains are matched was EUR 29,831 per QALY, which is below the EUR 40,000 threshold set by the Italian National Health Services. The ICER values range from EUR 13,736 (2017/2018) to EUR 72,153 (2013/2014). Averted influenza costs averaged EUR 23 per case, with fluctuations over the years. In most observed years, influenza vaccination was cost-effective from the healthcare providers’ standpoint. The exception was 2009–2010, due to a mismatch between vaccine and virus strains. Conclusions: This study highlights the economic viability of influenza vaccination, especially when virus and vaccine strains align. It demonstrates the potential of vaccination programs in preserving children’s health and well-being while managing healthcare costs.


  • Open Access

    Monitoring the Epidemiology of Otitis Using Free-Text Pediatric Medical Notes: A Deep Learning Approach

    by Corrado Lanera, Giulia Lorenzoni, Elisa Barbieri, Gianluca Piras, Arjun Magge, Davy Weissenbacher, Daniele Donà, Luigi Cantarutti, Graciela Gonzalez-Hernandez, Carlo Giaquinto, et al.

    Free-text information represents a valuable resource for epidemiological surveillance. Its unstructured nature, however, presents significant challenges in the extraction of meaningful information. This study presents a deep learning model for classifying otitis using pediatric medical records. We analyzed the Pedianet database, which includes data from January 2004 to August 2017. The model categorizes narratives from clinical record diagnoses into six types: no otitis, non-media otitis, non-acute otitis media (OM), acute OM (AOM), AOM with perforation, and recurrent AOM. Utilizing deep learning architectures, including an ensemble model, this study addressed the challenges associated with the manual classification of extensive narrative data. The performance of the model was evaluated according to a gold standard classification made by three expert clinicians. The ensemble model achieved values of 97.03, 93.97, 96.59, and 95.48 for balanced precision, balanced recall, accuracy, and balanced F1 measure, respectively. These results underscore the efficacy of using automated systems for medical diagnoses, especially in pediatric care. Our findings demonstrate the potential of deep learning in interpreting complex medical records, enhancing epidemiological surveillance and research. This approach offers significant improvements in handling large-scale medical data, ensuring accuracy and minimizing human error. The methodology is adaptable to other medical contexts, promising a new horizon in healthcare analytics.


  • Open Access

    Retrospective Analysis of the Real-World Use of Topical Antimicrobials in the Paediatric Population with Impetigo in Italy: Focus on the Role of Ozenoxacin 1% Cream

    by Elisa Barbieri, Sara Cavagnis, Riccardo Boracchini, Antonio Scamarcia, Angela Testa, Maria Grazia Ciarniello, Biancangela Martinelli, Luigi Cantarutti, Carlo Giaquinto, Anna Cantarutti

    Using electronic data from a large population-based network of Family Paediatricians (Pedianet), we aimed to describe the use of topical antimicrobials, including ozenoxacin 1% cream, in impetigo in children in Italy. We included 2929 children aged 6 months–14 years from 2016 to 2019 with at least one episode of impetigo treated with topical antimicrobials. Overall, 3051 cases of impetigo were included in the analysis. Treatment started in most cases on the same day as the impetigo diagnosis and lasted around eight days. In about 8% of the cases, a systemic antibiotic was prescribed after the topical antimicrobial, usually after 4–14 days. In this study, ozenoxacin was used in 8% of the cases. Treatment duration was significantly shorter for patients prescribed ozenoxacin compared to the whole study population (median of six vs. seven days, respectively). In contrast, the rate of treatment failure was similar. Very few adverse reactions were identified.


  • Open Access

    The Economic Burden of Pneumococcal Disease in Children: A Population-Based Investigation in the Veneto Region of Italy

    by Elisa Barbieri, Gloria Porcu, Tanaz Petigara, Francesca Senese, Gian Marco Prandi, Antonio Scamarcia, Luigi Cantarutti, Anna Cantarutti, Carlo Giaquinto

    Despite widespread childhood immunization programs, pneumococcal disease (PD) continues to be associated with significant clinical and economic burden worldwide. This retrospective study assessed the PD-related economic burden in children from the Veneto region of Italy following the introduction of a 13-valent pneumococcal conjugate vaccine (PCV13) to the Italian immunization schedule in 2010. Between 2010 and 2017, the annual incidences of pneumonia, acute otitis media (AOM), and invasive pneumococcal disease (IPD), as well as syndromic-disease-related episodes, declined. In our analysis of data from regional expenditure and healthcare resource utilization (HCRU) databases related to children < 15 years of age, we found that regional expenditures decreased between 2010 and 2017 for pneumonia (EUR 8.88 to EUR 3.59 million), AOM (EUR 3.78 to EUR 2.76 million), and IPD (EUR 1.40 to EUR 1.00 million). Despite reductions in PD-related expenditure following the introduction of PCV13, there continues to be an economic burden associated with PD in Veneto, Italy.


  • Open Access

    A Deep Learning Approach to Estimate the Incidence of Infectious Disease Cases for Routinely Collected Ambulatory Records: The Example of Varicella-Zoster

    by Corrado Lanera, Ileana Baldi, Andrea Francavilla, Elisa Barbieri, Lara Tramontan, Antonio Scamarcia, Luigi Cantarutti, Carlo Giaquinto, Dario Gregori

    The burden of infectious diseases is crucial for both epidemiological surveillance and prompt public health response. A variety of data, including textual sources, can be fruitfully exploited. Dealing with unstructured data necessitates the use of methods for automatic data-driven variable construction and machine learning techniques (MLT) show promising results. In this framework, varicella-zoster virus (VZV) infection was chosen to perform an automatic case identification with MLT. Pedianet, an Italian pediatric primary care database, was used to train a series of models to identify whether a child was diagnosed with VZV infection between 2004 and 2014 in the Veneto region, starting from free text fields. Given the nature of the task, a recurrent neural network (RNN) with bidirectional gated recurrent units (GRUs) was chosen; the same models were then used to predict the children’s status for the following years. A gold standard produced by manual extraction for the same interval was available for comparison. RNN-GRU improved its performance over time, reaching the maximum value of area under the ROC curve (AUC-ROC) of 95.30% at the end of the period. The absolute bias in estimates of VZV infection was below 1.5% in the last five years analyzed. The findings in this study could assist the large-scale use of EHRs for clinical outcome predictive modeling and help establish high-performance systems in other medical domains.


  • Open Access

    A Retrospective Analysis to Estimate the Burden of Invasive Pneumococcal Disease and Non-Invasive Pneumonia in Children <15 Years of Age in the Veneto Region, Italy

    by Elisa Barbieri, Gloria Porcu, Tianyan Hu, Tanaz Petigara, Francesca Senese, Gian Marco Prandi, Antonio Scamarcia, Luigi Cantarutti, Anna Cantarutti, Carlo Giaquinto

    Despite advances in preventative interventions, invasive pneumococcal disease and pneumonia cause significant morbidity and mortality in children. We studied the annual incidence of pneumococcal-specific and syndromic invasive disease and non-invasive pneumonia in children p = 0.46) throughout the study. Overall IR of non-invasive pneumonia was 10/1000 person-years and decreased significantly (−0.64, p = 0.026) over the study period. Following PCV13 introduction, the IRs of non-invasive pneumonia in children <15 years of age declined significantly, with no significant change in the IRs of pneumococcal-specific and syndromic invasive disease. There is a continuing clinical burden associated with pediatric pneumococcal diseases in Veneto, Italy.


  • Open Access

    A Retrospective Database Analysis to Estimate the Burden of Acute Otitis Media in Children Aged <15 Years in the Veneto Region (Italy)

    by Elisa Barbieri, Gloria Porcu, Tianyan Hu, Tanaz Petigara, Francesca Senese, Gian Marco Prandi, Antonio Scamarcia, Luigi Cantarutti, Anna Cantarutti, Carlo Giaquinto

    This study aimed to assess trends in the incidence of acute otitis media (AOM), a common childhood condition, following the introduction of the 13-valent pneumococcal conjugate vaccine (PCV13) in the Veneto region of Italy in 2010. AOM episodes (overall, simple, and recurrent (≥3 or ≥4 episodes in 6 or 12 months, respectively, with ≥1 episode in the preceding 6 months)) in children <15 years of age were identified in Pedianet from 2010–2017. Interrupted time series analyses were conducted to assess changes in the annual incidence rates (IRs) in early (2010–2013) and late (2014–2017) PCV13 periods. In total, 72,570 children (402,868 person-years) were identified; 21,048 had 41,683 AOM episodes. Mean annual AOM IR was 103/1000 person-years (95% confidence interval: 102–104), decreasing from 126 to 79/1000 person-years. AOM IRs were highest in children 2–4 years of age, followed by <2 and 5–14 years of age. Overall and simple AOM IRs decreased among children 0–14 years of age, including 2–4 and 5–14 years of age, while recurrent AOM IRs decreased in children <2 years of age. Following PCV13 introduction, AOM IRs decreased substantially in children <15 years of age, with the greatest benefit observed in older children, driven by a reduction in simple AOM IRs. AOM disease burden remains substantial.


  • Open Access

    Use of the Bacterial Lysate OM-85 in the Paediatric Population in Italy: A Retrospective Cohort Study

    by Anna Cantarutti, Elisa Barbieri, Antonio Scamarcia, Luigi Cantarutti, Cristina Canova, Carlo Giaquinto

    Background: In Italy, the bacterial lysate OM-85 (Broncho-Vaxom®, Broncho-Munal®, Ommunal®, Paxoral®, Vaxoral®) is registered for the prophylaxis of recurrent respiratory tract infections (RTIs) in adults and children above one year of age, but there are limited data on its use in the paediatric population. We aim to estimate the impact of OM-85 treatment on RTIs and antibiotic prescriptions in children. Methods: This study included children aged 1 to 14 years enrolled in Pedianet, a paediatric general practice research database, from January 2007 to June 2017, having at least one prescription of OM-85. Children with less than 12 months of follow-up before (PRE period) and after (POST period) the OM-85 prescription were excluded. The frequency of antibiotic prescriptions and the frequency of RTI episodes in the PRE and POST periods were compared through the post-hoc test. Subgroup analysis was performed in children with recurrent RTIs. Results: 1091 children received 1382 OM-85 prescriptions for a total follow-up of 619,525.5 person-years. Overall, antibiotic prescriptions decreased from a mean of 2.8 (SD (standard deviation) 2.7) prescriptions in the PRE period to a mean of 2.2 (SD 2.6) prescriptions in the POST period (p < 0.0001). RTIs decreased from a mean of 3.4 (SD 2.9) episodes in the PRE period to a mean of 2.5 (SD 2.6) episodes in the POST period (p < 0.0001). No change in antibiotic class was noted, and co-amoxiclav remained the preferred therapy in 28% of cases, followed by amoxicillin. These results were confirmed among children with recurrent RTIs. Conclusions: OM-85 is effective in preventing both antibiotic prescriptions and RTIs in children.